GLIPIZIDE

Post-LOE

glipizide

ANDAORALTABLET
Approved
Nov 1994
Lifecycle
Post-LOE
Competitive Pressure
30/100
Clinical Trials
8

Mechanism of Action

CLINICAL PHARMACOLOGY Mechanism of Action: The primary mode of action of glipizide in experimental animals appears to be the stimulation of insulin secretion from the beta cells of pancreatic islet tissue and is thus dependent on functioning beta cells in the pancreatic islets. In humans, glipizide…

Pharmacologic Class:

Sulfonylurea

Clinical Trials (5)

NCT01267448Phase 4Completed

Outpatient Discharge Therapy With Saxagliptin+MetforminXR vs GlipizideXL for Type 2 Diabetes With Severe Hyperglycemia

Started Sep 2014
100 enrolled
Diabetes Mellitus Type 2Hyperglycemia
NCT00856284Phase 3Completed

Efficacy and Safety of Alogliptin Plus Metformin Compared to Glipizide Plus Metformin in Patients With Type 2 Diabetes Mellitus

Started Mar 2009
2,639 enrolled
Type 2 Diabetes Mellitus
NCT00707993Phase 3Completed

Efficacy and Safety of Alogliptin Compared to Glipizide in Elderly Diabetics

Started Jun 2008
441 enrolled
Diabetes Mellitus
NCT00509236Phase 3Completed

Sitagliptin Versus Glipizide in Participants With Type 2 Diabetes Mellitus and End-Stage Renal Disease (MK-0431-073 AM1)

Started Oct 2007
129 enrolled
Diabetes Mellitus, Type 2End-Stage Kidney Disease
NCT00509262Phase 3Completed

Sitagliptin Versus Glipizide in Participants With Type 2 Diabetes Mellitus and Chronic Renal Insufficiency (MK-0431-063 AM1)

Started Oct 2007
426 enrolled
Diabetes Mellitus, Type 2Renal Insufficiency, Chronic